Oragenics Inc. has released its quarterly report for the third quarter of 2026, providing insights into its financial performance and operational activities. This filing is crucial for stakeholders as it highlights the company's current standing in the competitive pharmaceutical preparations industry.

In the filing dated November 12, 2026, Oragenics disclosed its performance metrics for the period ending September 30, 2026. The quarterly report sheds light on the company's revenue, expenses, and overall financial health, which are essential indicators for investors and analysts alike.

Background

Oragenics Inc. is a Florida-based company primarily engaged in the development and commercialization of innovative pharmaceutical preparations. The company trades under the ticker symbol OGEN on the New York Stock Exchange. As a smaller reporting company, Oragenics is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations.

What the Filing Says

The recent 10-Q filing provides a comprehensive overview of Oragenics' financial performance for the third quarter. Specific details regarding revenue, profit margins, and other financial metrics were included, reflecting the company's operations during this period. However, detailed numerical data was not available in the filing.

Impact

This filing may have significant implications for various stakeholders, including investors, analysts, and competitors in the pharmaceutical industry. Investors will closely analyze the reported figures to assess the company's financial stability and growth potential. Competitors will likely evaluate Oragenics' performance to benchmark their own strategies and market positioning.

What's Next

Following this filing, it is expected that Oragenics will continue to provide updates on its financial performance and operational strategies in future filings. However, the current filing does not specify any immediate next steps or upcoming events.

For more detailed information, stakeholders can access the full filing through the SEC's EDGAR database under accession number 0001493152-26-051477.